

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known Application Number 10/655,861 Filing Date September 5, 2003 First Named Inventor Yi Wang Art Unit 1644 Examiner Name P. Gambel Attorney Docket Number ALXN-P01-102	
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference concides, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <div style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center;"><i>(Use as many sheets as necessary)</i></div>		<div style="text-align: center;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/655,861</td> </tr> <tr> <td>Filing Date</td> <td>September 5, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Yi Wang</td> </tr> <tr> <td>Art Unit</td> <td>1644</td> </tr> <tr> <td>Examiner Name</td> <td>P. Gambel</td> </tr> <tr> <td>Attorney Docket Number</td> <td>ALXN-P01-102</td> </tr> </table>		Application Number	10/655,861	Filing Date	September 5, 2003	First Named Inventor	Yi Wang	Art Unit	1644	Examiner Name	P. Gambel	Attorney Docket Number	ALXN-P01-102
Application Number	10/655,861														
Filing Date	September 5, 2003														
First Named Inventor	Yi Wang														
Art Unit	1644														
Examiner Name	P. Gambel														
Attorney Docket Number	ALXN-P01-102														
Sheet	2	of	2												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kaplan, Mariana, "Eculizumab," Current Opinion in Investigational Drugs, Vol. 3(7); pp. 1017-1023 (2002).	
		Moongkarndi et al., "Immunological and functional properties of two monoclonal antibodies against human C5," Immunobiol. Vol. 165, page 323 (1983).	
		Moongkarndi et al., "Monoclonal antibodies against the fifth component of human complement," Immunobiol, Vol 162; page 397 (1982).	
		Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug, Press Release dated January 13, 2004.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.